[go: up one dir, main page]

FR24C1024I1 - COMBINATIONS OF DOLUTEGRAVIR AND LAMIVUDINE FOR THE TREATMENT OF HIV INFECTION - Google Patents

COMBINATIONS OF DOLUTEGRAVIR AND LAMIVUDINE FOR THE TREATMENT OF HIV INFECTION

Info

Publication number
FR24C1024I1
FR24C1024I1 FR24C1024C FR24C1024C FR24C1024I1 FR 24C1024 I1 FR24C1024 I1 FR 24C1024I1 FR 24C1024 C FR24C1024 C FR 24C1024C FR 24C1024 C FR24C1024 C FR 24C1024C FR 24C1024 I1 FR24C1024 I1 FR 24C1024I1
Authority
FR
France
Prior art keywords
dolutegravir
lamivudine
combinations
treatment
hiv infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1024C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare Co
Original Assignee
ViiV Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR24C1024(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ViiV Healthcare Co filed Critical ViiV Healthcare Co
Publication of FR24C1024I1 publication Critical patent/FR24C1024I1/en
Application granted granted Critical
Publication of FR24C1024I2 publication Critical patent/FR24C1024I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR24C1024C 2010-01-27 2024-06-06 COMBINATIONS OF DOLUTEGRAVIR AND LAMIVUDINE FOR THE TREATMENT OF HIV INFECTION Active FR24C1024I2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
PCT/US2011/022219 WO2011094150A1 (en) 2010-01-27 2011-01-24 Antiviral therapy
EP18161536.0A EP3351249A1 (en) 2010-01-27 2011-01-24 Antiviral therapy
EP15164931.6A EP2932970B1 (en) 2010-01-27 2011-01-24 Antiviral therapy
EP11737484.3A EP2531027B1 (en) 2010-01-27 2011-01-24 Therapeutic combination comprising dolutegravir, abacavir and lamivudine

Publications (2)

Publication Number Publication Date
FR24C1024I1 true FR24C1024I1 (en) 2024-07-26
FR24C1024I2 FR24C1024I2 (en) 2025-06-27

Family

ID=44319704

Family Applications (2)

Application Number Title Priority Date Filing Date
FR18C1043C Active FR18C1043I2 (en) 2010-01-27 2018-10-15 ANTIVIRAL THERAPY
FR24C1024C Active FR24C1024I2 (en) 2010-01-27 2024-06-06 COMBINATIONS OF DOLUTEGRAVIR AND LAMIVUDINE FOR THE TREATMENT OF HIV INFECTION

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR18C1043C Active FR18C1043I2 (en) 2010-01-27 2018-10-15 ANTIVIRAL THERAPY

Country Status (45)

Country Link
US (13) US20120295898A1 (en)
EP (6) EP3127542B1 (en)
JP (9) JP2013518107A (en)
KR (4) KR20170078868A (en)
CN (2) CN102791129B (en)
AP (1) AP3551A (en)
AU (1) AU2011209788C1 (en)
BR (1) BR112012018670A2 (en)
CA (4) CA2967453C (en)
CL (1) CL2012002080A1 (en)
CO (1) CO6602152A2 (en)
CR (1) CR20120423A (en)
CY (6) CY1116509T1 (en)
DK (4) DK3127542T3 (en)
DO (2) DOP2012000205A (en)
EA (4) EA032868B1 (en)
EC (1) ECSP12012106A (en)
ES (4) ES2543066T3 (en)
FI (2) FI3494972T3 (en)
FR (2) FR18C1043I2 (en)
HK (1) HK1250335A1 (en)
HR (4) HRP20240168T1 (en)
HU (6) HUE037812T2 (en)
IL (5) IL221007A (en)
LT (5) LT3494972T (en)
LU (1) LUC00090I2 (en)
MA (1) MA34002B1 (en)
ME (2) ME03058B (en)
MX (4) MX367937B (en)
MY (3) MY202778A (en)
NO (2) NO2932970T3 (en)
NZ (4) NZ627827A (en)
PE (2) PE20121524A1 (en)
PH (3) PH12012501537A1 (en)
PL (4) PL3127542T3 (en)
PT (4) PT3494972T (en)
RS (4) RS57323B1 (en)
SG (3) SG182614A1 (en)
SI (4) SI2932970T1 (en)
SM (4) SMT202400063T1 (en)
TN (1) TN2012000376A1 (en)
TR (1) TR201807704T4 (en)
UA (1) UA105556C2 (en)
WO (1) WO2011094150A1 (en)
ZA (1) ZA201205586B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032868B1 (en) 2010-01-27 2019-07-31 Вайв Хелткер Компани Combination for treating hiv infection
KR20150084772A (en) 2012-10-23 2015-07-22 시플라 리미티드 Pharmaceutical antiretroviral composition
MX344879B (en) 2012-12-21 2017-01-11 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use.
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
WO2014125124A1 (en) * 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
NO2865735T3 (en) 2013-07-12 2018-07-21
LT3019503T (en) 2013-07-12 2017-11-27 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
MX367057B (en) 2013-09-27 2019-08-02 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors.
IN2014MU00916A (en) 2014-03-20 2015-09-25 Cipla Ltd
US10300074B2 (en) 2014-06-04 2019-05-28 Sanford Burnham Prebys Medical Discovery Institute Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (en) 2014-06-20 2021-11-01 美商基利科學股份有限公司 Synthesis of polycyclic-carbamoylpyridone compounds
NO2717902T3 (en) 2014-06-20 2018-06-23
EP3177629B1 (en) 2014-07-29 2020-01-29 LEK Pharmaceuticals d.d. Novel hydrates of dolutegravir sodium
TWI738321B (en) 2014-12-23 2021-09-01 美商基利科學股份有限公司 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CA2980362C (en) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2017029225A1 (en) * 2015-08-14 2017-02-23 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company COMBINATION THERAPY
US20200147092A1 (en) * 2017-07-21 2020-05-14 Viiv Healthcare Company Regimens for treating hiv infections and aids
KR20200031658A (en) 2017-07-21 2020-03-24 비이브 헬쓰케어 컴퍼니 Therapy to treat HIB infection and AIDS
CA3078624A1 (en) * 2017-10-13 2019-04-18 Viiv Healthcare Company Bi-layer pharmaceutical tablet formulation
SI3938047T1 (en) 2019-03-22 2022-10-28 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
US20230270677A1 (en) * 2020-01-09 2023-08-31 University Of Washington Long-acting therapeutic agent combinations and methods thereof
WO2021173522A1 (en) 2020-02-24 2021-09-02 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
KR20230079137A (en) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 Crosslinked Tricyclic Carbamoylpyridone Compounds and Uses Thereof
PT4196479T (en) 2021-01-19 2024-01-03 Gilead Sciences Inc SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND THEIR USES
CN114230579A (en) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 Polycyclic carbamoylpyridone derivatives, process for their preparation and pharmaceutical compositions containing them
AU2023225805A1 (en) * 2022-02-28 2024-10-17 Jericho Sciences, Llc Methods for viral infections
TWI856796B (en) 2022-04-06 2024-09-21 美商基利科學股份有限公司 Bridged tricyclic carbamoylpyridone compounds and uses thereof

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (en) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко METHOD FOR TREATMENT OF RETROVIRAL INFECTIONS
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
JP2000515852A (en) * 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド A combination comprising VX478, zidovudine, FTC and / or 3TC for use in treating HIV
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
EP1063888A1 (en) 1998-03-27 2001-01-03 The Regents of the University of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (en) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Pharmaceutical formulations of efavirenz and disintegrants providing for increasing dissolution rate and process of manufacturing such tablets or capsules
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
DE20122916U1 (en) 2000-01-31 2009-12-10 Cook Biotech, Inc., West Lafayette stent valve
PT1377556E (en) 2001-04-10 2007-06-06 Pfizer Ltd Pyrazole derivatives for treating hiv
JO3429B1 (en) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv Hiv inhibiting pyrimidines derivatives
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
AR040242A1 (en) * 2002-06-04 2005-03-23 Glaxo Group Ltd PHARMACEUTICAL COMPOSITIONS
CA2481890A1 (en) 2002-06-27 2004-01-08 Medivir Ab Synergistic interaction of abacavir and alovudine
JP4996241B2 (en) * 2003-01-14 2012-08-08 ギリアード サイエンシーズ， インコーポレイテッド Compositions and methods for combination antiviral therapy
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AU2005211733A1 (en) * 2004-02-11 2005-08-25 Shionogi & Co., Ltd HIV integrase inhibitors
JP4285353B2 (en) 2004-03-05 2009-06-24 清水建設株式会社 Evaluation method of chemical emission
DE602005010413D1 (en) * 2004-04-14 2008-11-27 Zhenhong R Cai PHOSPHONATE ANALOGUE OF HIV INTEGRASE INHIBITOR COMPOUNDS
US8633219B2 (en) * 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
KR20070043043A (en) 2004-08-23 2007-04-24 테바 파마슈티컬 인더스트리즈 리미티드 Solid and Crystalline Ibandronate Sodium and Methods for Making the Same
PL1632232T6 (en) 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
KR101242962B1 (en) 2004-09-17 2013-03-13 아이데닉스 파마슈티칼스, 인코포레이티드 Phosphoindoles as HIV inhibitors
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
JP2008531716A (en) 2005-03-04 2008-08-14 スミスクライン ビーチャム コーポレーション Compound
US8129385B2 (en) * 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
JP2008542352A (en) 2005-06-01 2008-11-27 ビオアリアンス ファルマ A synergistic combination comprising a quinoline compound and other therapeutic agents for HIV infection
UA101141C2 (en) * 2005-12-30 2013-03-11 Гилиад Сайенсиз, Инк. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EA018544B1 (en) 2005-12-30 2013-08-30 Джилид Сайэнс, Инк. Method for treating retroviral infection
PL1981506T6 (en) * 2006-01-20 2021-07-12 Janssen Sciences Ireland Uc Long term treatment of hiv- infection with tcm278
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
EP2069303B1 (en) 2006-07-21 2016-03-30 Gilead Sciences, Inc. Antiviral protease inhibitors
NZ575831A (en) 2006-09-29 2011-12-22 Idenix Pharmaceuticals Inc Enantiomerically pure phosphoindoles as hiv inhibitors
WO2008103899A1 (en) 2007-02-23 2008-08-28 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
EP2118082B1 (en) 2007-02-23 2014-10-01 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CN101784532B (en) 2007-06-29 2014-10-22 韩国化学研究院 Novel HIV reverse transcriptase inhibitors
KR20100041798A (en) 2007-06-29 2010-04-22 한국화학연구원 Novel hiv reverse transcriptase inhibitors
KR20100040896A (en) 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 Modulators of pharmacokinetic properties of therapeutics
DK2175857T3 (en) * 2007-07-12 2013-12-02 Janssen R & D Ireland Crystalline Form of (E) 4 - [[4 - [[4- (2-CYANOETHENYL) -2,6-DIMETHYLPHENYL] AMINO] -2-PYRIMIDINYL] AMINO] BENZONITRIL
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
CN101990534A (en) 2007-11-01 2011-03-23 Uab研究基金会 Treating and preventing viral infections
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
EP2250185A4 (en) * 2008-01-03 2011-11-16 Virochem Pharma Inc Novel lupane derivatives
EP2240504A1 (en) 2008-01-03 2010-10-20 Virochem Pharma Inc. Novel c-21-keto lupane derivatives preparation and use thereof
CA2710679A1 (en) 2008-01-04 2009-07-16 Gilead Sciences, Inc. Inhibitors of cytochrome p450
CA2714049A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
ES2448766T3 (en) * 2008-07-25 2014-03-17 Viiv Healthcare Company Dolutegravir prodrugs
EP2376080B1 (en) * 2008-12-11 2017-09-13 Shionogi&Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
EP2376453B1 (en) 2008-12-11 2019-11-20 VIIV Healthcare Company Intermediates for carbamoylpyridone hiv integrase inhibitors
EA032868B1 (en) 2010-01-27 2019-07-31 Вайв Хелткер Компани Combination for treating hiv infection
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
EP2590971A4 (en) 2010-06-17 2014-12-10 Fuzians Biomedicals Inc COMPOUNDS USEFUL AS ANTIVIRAL AGENTS, COMPOSITIONS, AND METHODS OF USE
RU2623039C2 (en) 2011-04-01 2017-06-21 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Short-term acting dihydropyridines (clevidipine) for recovery after stroke

Also Published As

Publication number Publication date
JP2021091705A (en) 2021-06-17
US20120295898A1 (en) 2012-11-22
LTC2932970I2 (en) 2022-04-25
MY202778A (en) 2024-05-21
PL3127542T3 (en) 2019-03-29
EA201290583A1 (en) 2013-04-30
DOP2021000147A (en) 2022-01-16
BR112012018670A2 (en) 2018-02-06
PH12016500195A1 (en) 2016-12-05
SMT201500177B (en) 2015-09-07
EP2932970A1 (en) 2015-10-21
MX367938B (en) 2019-09-12
CN105311033B (en) 2019-05-07
EP2932970B1 (en) 2018-03-21
CY1120457T1 (en) 2019-07-10
AP2012006445A0 (en) 2012-08-31
JP2018127473A (en) 2018-08-16
PH12018502489A1 (en) 2020-06-15
PL3494972T3 (en) 2024-05-27
PE20160180A1 (en) 2016-05-04
ZA201205586B (en) 2014-01-29
EP2531027B1 (en) 2015-05-06
ES2543066T3 (en) 2015-08-14
SMT201800594T1 (en) 2019-01-11
HK1209629A1 (en) 2016-04-08
CY2018029I2 (en) 2019-07-10
ME03058B (en) 2019-01-20
IL245182A0 (en) 2016-06-30
US20200230147A1 (en) 2020-07-23
IL281959B (en) 2021-12-01
EP3351249A1 (en) 2018-07-25
MY188334A (en) 2021-11-30
RS57728B1 (en) 2018-12-31
EA202190473A3 (en) 2021-12-31
CY1121040T1 (en) 2019-12-11
DK2932970T3 (en) 2018-05-28
US20160339033A1 (en) 2016-11-24
UA105556C2 (en) 2014-05-26
NZ627824A (en) 2016-02-26
CA2787691A1 (en) 2011-08-04
CA3003988A1 (en) 2011-08-04
JP2016145204A (en) 2016-08-12
EP4316599A2 (en) 2024-02-07
CL2012002080A1 (en) 2012-11-30
LTPA2018013I1 (en) 2018-11-12
SMT201800290T1 (en) 2018-07-17
EP2531027A1 (en) 2012-12-12
HUS1800042I1 (en) 2018-11-28
LTC3494972I2 (en) 2025-11-10
DK3494972T3 (en) 2024-01-29
JP2019167371A (en) 2019-10-03
EP2531027A4 (en) 2013-07-03
JP2023085431A (en) 2023-06-20
IL267658A (en) 2019-08-29
ME02182B (en) 2015-10-20
IL257267B (en) 2019-08-29
FI3494972T3 (en) 2024-03-01
EP3494972A1 (en) 2019-06-12
EP3494972B1 (en) 2023-12-13
CY1126771T1 (en) 2025-05-09
US11234985B2 (en) 2022-02-01
DK2531027T3 (en) 2015-07-20
NZ627826A (en) 2016-01-29
MX356891B (en) 2018-06-19
AP3551A (en) 2016-01-18
CY2024017I1 (en) 2025-05-09
ECSP12012106A (en) 2013-05-31
CR20120423A (en) 2012-11-22
EA202190473A2 (en) 2021-06-30
KR101830715B1 (en) 2018-04-04
RS65183B1 (en) 2024-03-29
KR101964923B1 (en) 2019-04-02
CY2018029I1 (en) 2019-07-10
SI3127542T1 (en) 2018-11-30
WO2011094150A1 (en) 2011-08-04
FR18C1043I1 (en) 2018-11-30
HRP20180855T1 (en) 2018-06-29
HUE065569T2 (en) 2024-06-28
JP2013518107A (en) 2013-05-20
AU2011209788A1 (en) 2012-08-16
CN105311033A (en) 2016-02-10
RS54123B1 (en) 2015-12-31
NZ601319A (en) 2014-08-29
MA34002B1 (en) 2013-02-01
KR20180078358A (en) 2018-07-09
LUC00090I2 (en) 2019-01-08
TR201807704T4 (en) 2018-06-21
KR20160111536A (en) 2016-09-26
PE20121524A1 (en) 2012-12-03
JP6268386B2 (en) 2018-01-31
FR18C1043I2 (en) 2019-10-11
HUE026849T2 (en) 2016-08-29
EP3127542A1 (en) 2017-02-08
HRP20150770T1 (en) 2015-08-28
TN2012000376A1 (en) 2014-01-30
LT3127542T (en) 2018-11-26
US20170079982A1 (en) 2017-03-23
ES2688925T3 (en) 2018-11-07
EA201690872A3 (en) 2016-12-30
ES2670811T3 (en) 2018-06-01
LT3494972T (en) 2024-03-12
PL2932970T3 (en) 2018-08-31
RS57323B1 (en) 2018-08-31
HK1179522A1 (en) 2013-10-04
CO6602152A2 (en) 2013-01-18
PH12012501537A1 (en) 2018-02-07
PT3127542T (en) 2018-11-26
NZ627827A (en) 2016-02-26
PH12016500195B1 (en) 2021-08-04
US20180200254A1 (en) 2018-07-19
HRP20181531T1 (en) 2018-11-16
IL257267A (en) 2018-03-29
EA032868B1 (en) 2019-07-31
EA025176B1 (en) 2016-11-30
DOP2012000205A (en) 2012-10-15
EA037601B1 (en) 2021-04-20
EP4316599A3 (en) 2024-04-10
CA3060290A1 (en) 2011-08-04
JP2017008087A (en) 2017-01-12
SMT202400063T1 (en) 2024-03-13
PT2531027E (en) 2015-09-16
CA3003988C (en) 2020-01-07
SG10201509476RA (en) 2015-12-30
DK3127542T3 (en) 2018-11-12
CA3060290C (en) 2022-07-12
KR20120128640A (en) 2012-11-27
MY207233A (en) 2025-02-07
EP3127542B1 (en) 2018-08-22
KR20170078868A (en) 2017-07-07
AU2011209788C1 (en) 2014-08-28
CA2967453C (en) 2018-07-17
SI2932970T1 (en) 2018-07-31
EA201690872A2 (en) 2016-08-31
LTPA2024516I1 (en) 2024-06-25
US20170216284A1 (en) 2017-08-03
JP7724619B2 (en) 2025-08-18
PT2932970T (en) 2018-06-08
AU2011209788B2 (en) 2014-02-06
HUE040554T2 (en) 2019-03-28
SI3494972T1 (en) 2024-03-29
HK1250335A1 (en) 2018-12-14
EA201892277A1 (en) 2019-03-29
PL2531027T3 (en) 2016-01-29
SG182614A1 (en) 2012-08-30
LT2932970T (en) 2018-06-25
JP2022071126A (en) 2022-05-13
IL267658B (en) 2021-04-29
US20150238496A1 (en) 2015-08-27
US20180098992A1 (en) 2018-04-12
CA2967453A1 (en) 2011-08-04
SI2531027T1 (en) 2015-08-31
JP2025131664A (en) 2025-09-09
FR24C1024I2 (en) 2025-06-27
HRP20240168T1 (en) 2024-04-26
IL221007A (en) 2016-06-30
NO2932970T3 (en) 2018-08-18
NO2018036I1 (en) 2018-10-15
CY1116509T1 (en) 2017-03-15
CA2787691C (en) 2018-07-17
PT3494972T (en) 2024-02-12
IL221007A0 (en) 2012-09-24
MX2012008774A (en) 2012-08-17
US20170281636A1 (en) 2017-10-05
US20250017939A1 (en) 2025-01-16
SG10201707183TA (en) 2017-10-30
IL245182B (en) 2018-04-30
CN102791129A (en) 2012-11-21
ES2969969T3 (en) 2024-05-23
IL281959A (en) 2021-05-31
KR101883750B1 (en) 2018-07-31
CY2024017I2 (en) 2025-05-09
HUE037812T2 (en) 2018-09-28
HUS2400017I1 (en) 2024-06-28
CN102791129B (en) 2015-09-30
US20170119777A1 (en) 2017-05-04
US10426780B2 (en) 2019-10-01
MX367937B (en) 2019-09-12
US20210401850A1 (en) 2021-12-30
FIC20240016I1 (en) 2024-05-31
US20160199379A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
FR24C1024I2 (en) COMBINATIONS OF DOLUTEGRAVIR AND LAMIVUDINE FOR THE TREATMENT OF HIV INFECTION
EP2611465A4 (en) NEUTRALIZING ANTI-VIRUS ANTIBODIES FOR HUMAN IMMUNODEFICIENCY (HIV)
EP2638534A4 (en) ENHANCEMENT OF COGNITION IN THE PRESENCE OF DISTRACTION AND / OR INTERRUPTION
EP2429993A4 (en) INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
EP2421589A4 (en) DETECTION OF ASYNCHRONOUS
EP2582683A4 (en) TREATMENT OF DROP AND HYPERURICEMIA
EP2596741A4 (en) ENDOSCOPE, AND TREATMENT INSTRUMENT FOR ENDOSCOPE
EP2643018A4 (en) ANTI-IL-6 ANTIBODIES USED FOR THE TREATMENT OF STOMATITIS
EP2450046A4 (en) MEDICALLY ACTIVE COMPOSITION FOR THE TREATMENT OF BRONCHITIS AND PREPARATION THEREOF
EP2376661A4 (en) SIMULTANEOUS DETERMINATION OF ANEUPLOIDIA AND FETAL FRACTION
EP2744427A4 (en) MEDICAL INSTRUMENT HAVING MECHANISMS OF FLEXIBLE JAW AND / OR FLEXIBLE WRIST
EP2646043A4 (en) NEW CICLOSPORINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
EP2254582A4 (en) METHODS OF TREATING VIRAL INFECTIONS
EP2307035A4 (en) TREATMENT OF EPILEPSY
EP2330892A4 (en) METHODS OF TREATMENT WITH AMMONIA-DEACTIVATING MEDICINES
EP2855521A4 (en) COMPOSITIONS AND METHODS ASSOCIATED WITH THE PREVENTION AND TREATMENT OF RABIC INFECTION
EP2632550A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF HIV ASSOCIATED DIARRHEA
EP2800575A4 (en) TREATMENT OF SUBARACHNOID HEMORRHAGIA AND ISCHEMIA
EP2429517A4 (en) APPROPRIATE COMPOSITIONS FOR THE TOPIC TREATMENT OF FUNGAL INFECTIONS OF SKIN AND NAILS
BR112012016492A2 (en) "disposable article of clothing"
EP2582391A4 (en) TREATMENT OF ARTHRITIS
EP2624821A4 (en) POLYTHERAPY FOR THE TREATMENT OF DEPRESSION AND OTHER NON-INFECTIOUS DISEASES
EP2667745A4 (en) MECHANISM OF INSERTION AND SOLICITATION
EP2707486A4 (en) DIAGNOSIS AND TREATMENT OF FRIEDREICH ATAXIA
EP2120988A4 (en) TREATMENT OF HEPATITIS C VIRUS INFECTION